Podimetrics, the maker of a smart foot mat that detects warning signs of diabetic foot ulcers, said on Thursday it raised $13.4 million in a funding round led by a group of investors, including venture capital firm Scientific Health Development.
Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.
The active ingredients of commonly-used sunscreens end up in the bloodstream at much higher levels than current U.S. guidelines from health regulators and warrant further safety studies, according to a small study conducted by U.S. Food and Drug Administration researchers and published on Monday.
(Reuters Health) - Teens with painful chronic illnesses may find that YouTube can provide a support network, a new study suggests.
CVS Health Corp on Wednesday raised its full-year profit forecast and reported first-quarter earnings that topped Wall Street estimates due to growth in its Aetna health insurance business, and as drug prices fell within its expectations.
Merck & Co Inc reported higher-than-expected first-quarter profit on Tuesday on increased demand for vaccines and cancer immunotherapy Keytruda, and the U.S. drugmaker raised its 2019 earnings and revenue forecasts.
(Reuters Health) - College athletes may face a higher risk for sport-related concussions if they have insomnia or even if they're just chronically sleepy, a new study suggests.
Gilead Sciences Inc's experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another trial.
Boston Scientific Corp on Wednesday posted a rare first-quarter profit and revenue miss and lowered the top end of its 2019 sales growth forecast as the medical device maker faces regulatory scrutiny for some of its products.
Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches after the company found the treatment was unlikely to meet the main goal of a late-stage trial.